Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab versus Chemotherapy in Metastatic Urothelial Carcinoma
2024-515506-11-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of livmoniplimab and budigalimab in transitional cell carcinoma (TCC) and urothelial carcinoma (UC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2024-515506-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515506-11-00.